ClinicalTrials.gg
RecruitingNCT07701096RESET-COPDUpdated Oct 19, 2026

RESET-COPD Cohort: Real-Time Monitoring and Early Warning in COPD Patients Receiving Home NPPV

An observational study in Pulmonary Disease, Chronic Obstructive (COPD), Chronic Respiratory Failure With Hypercapnia and Noninvasive Ventilation, sponsored by Beijing Chao Yang Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Primary conditionPulmonary Disease, Chronic ObstructiveRegistry: Lung DiseasesReclassifiedWhy we changed it
Registry
Lung Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Disease, Chronic Obstructive
Why
  1. The study's listed conditions name Pulmonary Disease, Chronic Obstructive, a narrower term within Lung Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Beijing Chao Yang Hospital · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 19, 2026Now RecruitingNow Enrolling by invitation+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Pulmonary Disease, Chronic Obstructive by Beijing Chao Yang Hospital — 6 open to participants now, 6 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Beijing Chao Yang Hospital.

Started
2026
with 2 others
Observational
7 of 13
5 open now
Registered
12th of 13
by date

Among the 13 studies in Pulmonary Disease, Chronic Obstructive by Beijing Chao Yang Hospital, this one is one of 3 that started in 2026, is one of 7 observational ones, and was the 12th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

6 of the 13 studies in Pulmonary Disease, Chronic Obstructive by Beijing Chao Yang Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Pulmonary Disease, Chronic Obstructive by Beijing Chao Yang Hospital, or all of them as a file.
02

Study summary

This is a multicenter prospective cohort study designed to develop and validate a multisensor-based real-time monitoring and intelligent early warning model for acute exacerbations in patients with chronic obstructive pulmonary disease receiving home noninvasive positive pressure ventilation.

Eligible participants will be adults with severe COPD and chronic hypercapnic respiratory failure who are receiving or newly initiating home noninvasive positive pressure ventilation. Participants will undergo baseline assessment and follow-up visits at 3, 6, and 12 months. Clinical data, arterial blood gas measurements, pulmonary function, exercise capacity, symptom burden, health-related quality of life, psychological status, home noninvasive ventilation parameters, adherence, device-related adverse events, healthcare utilization, acute exacerbations, hospitalizations, intensive care unit admissions, invasive mechanical ventilation, and mortality will be collected.

Continuous physiological monitoring data, will be used to construct individualized stable baseline values and to identify digital warning signals. Digital warning events will be further adjudicated through symptom confirmation, treatment and healthcare utilization verification, exclusion of alternative explanations, and investigator assessment.

The study aims to establish a longitudinal clinical and physiological dataset for COPD patients receiving home noninvasive ventilation and to evaluate the performance of a multisensor-based early warning model for clinically confirmed acute exacerbations of COPD.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive (COPD)
  • Chronic Respiratory Failure With Hypercapnia
  • Noninvasive Ventilation

Browse trials for

04

In context

Pulmonary Disease, Chronic Obstructive Reclassified

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

This study's planned enrollment of 250 is above the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

Beijing Chao Yang Hospital is the lead sponsor of 142 studies on the registry; 51 are open to participants now.

Compared within Pulmonary Disease, Chronic Obstructive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study participants will be selected from adult patients with severe chronic obstructive pulmonary disease and chronic hypercapnic respiratory failure who are managed at participating clinical centers and who are receiving or newly initiating home noninvasive positive pressure ventilation. The study population will include clinically stable COPD patients with severe airflow limitation and persistent hypercapnia who are suitable for home NPPV follow-up and multisensor real-time monitoring.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Diagnosis of according to GOLD 2026 criteria, with post-bronchodilator /FVC \< 0.70.
  • Severe airflow limitation, defined as FEV1 \< 50% of predicted value, corresponding to GOLD grade III-IV.
  • Chronic hypercapnia, defined as arterial PaCO₂ ≥ 52 mmHg (approximately 7.0 kPa) in a clinically stable state (no acute exacerbation of COPD within at least 4 weeks before enrollment), with arterial blood gas analysis performed in the sitting position at rest and after discontinuation of NPPV for at least 2 hours.

Exclusion criteria

Exclusion Criteria:

  • Chronic respiratory failure caused by diseases other than , including neuromuscular diseases, chest wall deformity, obstructive sleep apnea, or severe obesity with > 35 kg/m².
  • Severe cardiovascular disease, including class IV heart failure or unstable angina.
  • Severe renal disease receiving long-term renal replacement therapy.
  • Expected survival of less than 1 year, including active or end-stage systemic disease.
  • Inability to complete the study, including cognitive impairment, psychiatric disease, inability to cooperate with NPPV, inability to use wearable devices, or inability to complete follow-up.
  • Refusal to participate in the study or refusal to sign .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

Interventions

  • OtherNot applicable- observational study

    For this observational study, participants are not assigned an intervention as part of the study.

07

What researchers measure

Primary outcomes

  1. One-year hospitalization rate due to acute exacerbation of COPD

    The proportion of participants who experience at least one hospitalization due to clinically confirmed acute exacerbation of COPD during the 12-month follow-up period. Hospitalization due to acute exacerbation of COPD will be confirmed based on symptom worsening, treatment or healthcare utilization, exclusion of alternative explanations, and investigator adjudication.

    Time frame: 12 months

Secondary outcomes

  1. Number of COPD-related hospitalizations

    Number of hospitalizations related to acute exacerbation of COPD during follow-up.

    Time frame: 12 months

  2. Number of acute exacerbations of COPD

    The total number of hospitalizations due to clinically confirmed acute exacerbation of COPD during the 12-month follow-up period.

    Time frame: 12 months

  3. Emergency department visit rate due to acute exacerbation of COPD

    The proportion of participants with at least one emergency department visit due to clinically confirmed acute exacerbation of COPD during the 12-month follow-up period.

    Time frame: 12 months

  4. Intensive care unit admission rate due to acute exacerbation of COPD

    The proportion of participants with at least one intensive care unit admission due to clinically confirmed acute exacerbation of COPD during the 12-month follow-up period.

    Time frame: 12 months

  5. Invasive mechanical ventilation rate due to acute exacerbation of COPD

    The proportion of participants who receive invasive mechanical ventilation due to clinically confirmed acute exacerbation of COPD during the 12-month follow-up period.

    Time frame: 12 months

  6. One-year all-cause mortality

    The proportion of participants who die from any cause during the 12-month follow-up period.

    Time frame: 12 months

08

Study locations

1 of 1 sites recruiting
09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jul 2028, 22 months after the start.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 22 months is below that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 14, 2026
StartActual
Sep 29, 2026was Aug 2026
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 31, 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation→Recruiting
changed Oct 15, 2026 · changed Oct 19, 2026
Sites
1 site added — first site in China. Beijing Chao-Yang Hospital, Capital Medical University is now Recruiting
Show site
  • Beijing Chao-Yang Hospital, Capital Medical University · Beijing, China
across 2 updates, Oct 15, 2026 – Oct 19, 2026
Start date
Aug 1, 2026→Sep 29, 2026 (actual)
Oct 15, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedChronic hypercapnic respiratory failurehypercapnia, defined as arterial PaCO₂ ≥ 5352 mmHg or ≥(approximately 7.0 kPa while breathing room air) in a clinically stable state, that is, (no acute exacerbation of COPD within at least 4 weeks before enrollment), with arterial blood gas analysis performed in the sitting position at rest and after discontinuation of NPPV for at least 2 hours.
Oct 15, 2026
Interventions
Added Not applicable- observational study; removed Device: Home NPPV
Oct 19, 2026
Contact
Study contact now listed: added x•••@163.com · •••7587. See the current contact
Oct 19, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Beijing Chao-Yang Hospital, Capital Medical University · Beijing, ChinaContact added x•••@163.com · •••7587
Oct 19, 2026
Show all 2 updates
  1. Oct 19, 2026
    Enrolling by invitation→Recruiting
    Beijing Chao-Yang Hospital, Capital Medical University is now Recruiting
    Interventions Added Not applicable- observational study; removed Device: Home NPPV
    Contact Study contact now listed: added x•••@163.com · •••7587. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Beijing Chao-Yang Hospital, Capital Medical University · Beijing, ChinaContact added x•••@163.com · •••7587
    + 1 other change: verification date
  2. Oct 15, 2026
    Not yet recruiting→Enrolling by invitation
    1 site added — first site in China
    Show site
    • Beijing Chao-Yang Hospital, Capital Medical University · Beijing, China
    Start date Aug 1, 2026→Sep 29, 2026 (now actual)
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedChronic hypercapnic respiratory failurehypercapnia, defined as arterial PaCO₂ ≥ 5352 mmHg or ≥(approximately 7.0 kPa while breathing room air) in a clinically stable state, that is, (no acute exacerbation of COPD within at least 4 weeks before enrollment), with arterial blood gas analysis performed in the sitting position at rest and after discontinuation of NPPV for at least 2 hours.

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07701096
Responsible party
Sponsor
First posted
Jul 14, 2026
Start date
Sep 29, 2026
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Oct 19, 2026

Study contacts

Zujin Luo, MD
Contact
xmjg2002@163.com
+86-13810497587

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion